Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …

Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …

Tumors responding to immune checkpoint inhibitors (ICIs) have a higher level of immune
infiltrates and/or an Interferon (IFN) signature indicative of a T-cell-inflamed phenotype …

Background Immune checkpoint inhibitors (ICI) are approved for treatment of recurrent or
metastatic oropharyngeal head and neck squamous cell carcinoma in the first-and second …

Squamous cell carcinoma of the head and neck (SCCHN) is among the most prevalent
cancer types worldwide. Despite multimodal therapeutic approaches that include surgical …

Head and neck squamous cell carcinoma (HNSCC) is a very aggressive disease with a poor
prognosis for advanced-stage tumors. Recent clinical, genomic, and cellular studies have …

Chemotherapy and radiotherapy predominantly improve the clinical outcomes of patients
with human papillomavirus (HPV)-related head and neck squamous cell carcinoma …

Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancers
worldwide. More than half of patients with HNSCC eventually experience disease …

Simple Summary Head and neck cancer (HNC) is the sixth most common cancer, causing
almost half a million deaths worldwide every year. The two subtypes of HNC are distinctly …

Preclinical data suggest that head and neck squamous cell carcinoma (HNSCC) is a
profoundly immunosuppressive disease, characterized by abnormal secretion of …